Finding the best way to make two cancer-targeting T cells for the price of one
Professor John Anderson at University College London hopes to develop a cost-effective CAR T-cell combination therapy.
Unravelling the behaviour of individual lymphoma cells to find out why the cancer can relapse or resist treatment
Professor Suzanne Turner will investigate the behaviour of individual lymphoma cells in order to find out why treatments fail.
Investigating the role of SET in childhood acute myeloid leukaemia to develop new treatments
Dr Maria Teresa Esposito hopes to learn more about a gene called SET in leukaemia and will test the best medicines to fight it.
Targeting metabolism in aggressive childhood blood cancers
Prof Jonathan Bond and Dr Marie-Claire Fitzgerald aim to find a treatment that can exploit a key weakness of acute myeloid leukaemia.
Finding the most beneficial dose of fludarabine to optimise CAR-T therapy
Dr Shelby Barnett and Dr Geoff Shenton will monitor crucial drug levels in patients' blood in order to improve CAR T therapy protocols.
Stopping the alpha - a potential new treatment approach for osteosarcoma
Professor Plevin and Dr Margaret Cunningham will investigate an enzyme that might play a role in osteosarcoma development, and see whether this could form the basis of a new type of treatment.
Exploring surrounding epigenetic influences in Ewing sarcoma
Dr Sara Sánchez Molina is investigating how a certain gene drives Ewing sarcoma in order to find a better way to treat it.
Exploring potential indicators of the likely course of disease: analysing blood samples from patients recruited to the rEECur clinical trial
Professor Martin McCabe aims to understand whether blood-based biomarkers could help predict Ewing sarcoma survival.
Evaluating a new antibody-based targeted treatment for medulloblastoma
Dr Laura Donovan is testing a targeted treatment for medulloblastoma in the hopes of giving incurable patients new treatment options.